Xi'An Xintong Pharmaceutical Research Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2000-05-30
- Employees
- -
- Market Cap
- -
- Website
- http://www.xtyw.com.cn
Clinical Trials
7
Active:1
Completed:0
Trial Phases
4 Phases
Phase 1:4
Phase 2:1
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Not Applicable
1 (14.3%)Phase 2
1 (14.3%)Phase 3
1 (14.3%)A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
Not Applicable
Active, not recruiting
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: HTS 20mgDrug: HTS 30mgDrug: HTS 40mgDrug: TAF 25mg
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 1444
- Registration Number
- NCT07203118
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, changchun, China
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: Test drug XT1061 capsules and placebo,Single dose groupDrug: Test drug XT1061 capsules and placebo，Food Impact GroupDrug: Test drug XT1061 capsules and placebo，Multiple dosing group
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT06280534
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT06141096
- Locations
- 🇨🇳
Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- EfficacySafety IssuesMTD
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT06141109
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB
Phase 1
Recruiting
- Conditions
- SafetyEfficacyPharmacokinetics
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06122454
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
- Prev
- 1
- 2
- Next
News
No news found